ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1450

Integrative Analysis of DNA Methylation and Gene Expression in Monocytes from Primary Antiphospholipid Syndrome Patients Identifies a Gene Expression Signature Associated with Their Atherothrombotic Phenotype
Abstract Number: 1462

Intensity and Duration of Silica Exposure Increase Rheumatoid Arthritis Risk Among Coal Miners
Abstract Number: 0990

Interferon Lambda Promotes Human Plasma Cell Differentiation in Lupus and Healthy Donors
Abstract Number: 0171

Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, T Cells, B Cells, and NK Cells in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI
Abstract Number: 1525

Intergenic HLA Variants in African American Patients with Systemic Sclerosis Regulate Expression of HLA-DRB1
Abstract Number: 0099

Interleukin 6 Concentration in Synovial Fluid of Patients with Different Types of Arthritis
Abstract Number: 0335

Interleukin-17 Blockade Leads to Shifts from Stage-based Towards Response-based Disease Clusters- Comparative Data from Very Early and Established Psoriatic Arthritis
Abstract Number: 1519

Interleukin-17D, a Cytokine Derived from Stromal Cells, Attenuates Joint Inflammation
Abstract Number: 0497

Interleukin-23 Acts Directly on Podocytes and Contributes to the Development of Glomerulonephritis
Abstract Number: 1089

Intermuscular Adipose Tissue in Patients with Systemic Lupus Erythematosus
Abstract Number: 0829

International Comparison of Japanese and US Cross Country Utilization of RA Medications
Abstract Number: 1431

Interstitial Lung Disease in Patients with ANCA Associated Vasculitis – a Prospective Single Centre Study
Abstract Number: 1524

Interstitial Lung Disease, Kidney Inflammation and Myositis Are Induced by Transfer of PBMC Derived from Systemic Sclerosis Patients into Rag2-/-/ IL2rg-/- mice
Abstract Number: 0591

Intervention to Improve SLE Medication Adherence Using Surescripts Pharmacy Refill Data
Abstract Number: 1852

Intestinal Permeability in the Adjuvant Induced Arthritis Model: Preliminary Study and Impact of NSAIDs

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].